This thesis describes a novel method to reversibly and safely block nerve conduction using a low frequency alternating current (LFAC) waveform at 1 Hz applied through a bipolar extrafascicular electrode. This work follows up on observations made on excised mammalian peripheral nerves and earthworm nerve cords. An<i> in-situ</i> electrophysiology setup was used to assess the LFAC<br>waveform on propagating action potentials (APs) within the cervical vagus nerve in anaesthetized Sprague-Dawley rats (n = 12). Two sets of bipolar cuff or hook electrodes were applied unilaterally to the cervical vagus nerve, which was crushed rostral to the electrodes to exclude reflex effects<br>on the animal. Pulse stimulation was applied to the rostral electrode, while the LFAC conditioning waveform was applied to the caudal electrode. The efferent volley, if unblocked, elicits acute bradycardia and hypotension. The degree of block of the vagal stimulation induced bradycardia<br>was used as a biomarker. Block was assessed by the ability to reduce the bradycardic drive by monitoring the heart rate (HR) and blood pressure (BP) during LFAC alone, LFAC with vagal stimulation, and vagal stimulation alone. LFAC applied via a hook electrode (n = 7) achieved 86.6 +/- 11% block at current levels 95 +/- 38 uAp (current to peak). When applied via a cuff electrode (n = 5) 85.3 +/- 4.60% block was achieved using current levels of 110 +/- 65 uAp. Furthermore, LFAC was explored on larger vagal afferent fibers in larger human sized nerve bundles projecting to effects mediated by a reflex. The effectiveness of LFAC was assessed in an <i>in-situ</i> electrophysiological setup on the left cervical vagus in anaesthetized domestic swine (n = 5). Two bipolar cuff electrodes were applied unilaterally to the cervical vagus nerve, which was crushed caudal to the electrodes to eliminate cardiac effects. A tripolar extrafascicular cuff electrode was placed most rostral on the nerve for recording of propagating APs induced by<br>electrical stimulation and blocked via the LFAC waveform.<br>Standard pulse stimulation was applied to the left cervical vagus to induce the Hering-Breuer reflex. If unblocked, the activation of the Hering-Breuer reflex would cause breathing to slow down and potentially cease. Block was quantified by the ability to reduce the effect of the Hering-Breuer<br>reflex by monitoring the breathing rate during LFAC alone, LFAC and vagal stimulation, and vagal stimulation alone. LFAC achieved 87.2 +/- 8.8% (n = 5) block at current levels of 0.8 +/- 0.3 mAp. Compound nerve action potentials (CNAP) were monitored directly. They show changes<br>in nerve activity during LFAC, which manifests itself as the slowing and amplitude reduction of components of the CNAPs. Since the waveform is balanced, all forward reactions are reversed, leading to a blocking method that is similar in nature to DC block without the potential issues of<br>toxic byproduct production. These results suggest that LFAC can achieve a high degree of nerve block in both small and large nerve bundles, resulting in the change in behavior of a biomarker, <i>in-vivo </i>in the mammalian nervous system at low amplitudes of electrical stimulation that are within the water window of the electrode.<br>

No description available.

Introduction & Objectifs : Pour assurer l’analgésie postopératoire, l’anesthésiste dispose, en plus des différentes classes de médicaments administrés par voie orale ou intraveineuse, de diverses techniques pour bloquer l’influx nerveux douloureux en administrant les anesthésiques locaux (AL) de manière centrale ou périphérique. La ropivacaïne (ROP), un AL à longue durée d’action, est un médicament de première intention partout dans le monde, en raison de sa grande efficacité et de son faible risque de toxicité. Contrairement à certains pays, la ROP n'est toujours pas indiquée au Canada pour la rachianesthésie (bloc central) en raison d'un manque de données probantes. Jusqu'à présent, les efforts de recherche ont essentiellement porté sur la sécurité ainsi que sur la durée d’action du médicament lorsqu’administré par voie spinale. De plus, les doses optimales de ROP pour l’anesthésie régionale périphérique ne sont pas encore précisément connues. La posologie devrait être adaptée au site d’administration ainsi qu’à l’intensité et la durée du stimulus produit par la chirurgie. Ultimement, cela permettrait aux cliniciens d’identifier le régime optimal en fonction des facteurs démographiques qui pourraient affecter la pharmacocinétique (PK) et la pharmacodynamie (PD) de l’AL (objectif global de ces travaux). Validation de la Méthode Analytique Manuscrit 1 : Une méthode analytique spécifique et sensible permettant de déterminer les concentrations plasmatiques de ROP a d’abord été optimisée et validée. Validation du Biomarqueur Manuscrit 2 : Nous avons ensuite mis au point et évalué la fiabilité d’une méthode quantitative basée sur la mesure du seuil de perception sensorielle (CPT) chez le volontaire sain. Ce test nécessite l’application d’un courant électrique transcutané qui augmente graduellement et qui, selon la fréquence choisie, est capable de stimuler spécifiquement les fibres nerveuses impliquées dans le cheminement de l’influx nerveux douloureux. Les résultats obtenus chez les volontaires sains indiquent que la mesure CPT est fiable, reproductible et permet de suivre l’évolution temporelle du bloc sensitif. Études cliniques Manuscrit 3 : Nous avons ensuite caractérisé, pendant plus de 72 h, l’absorption systémique de la ROP lorsqu’administrée pour un bloc du nerf fémoral chez 19 patients subissant une chirurgie du genou. Le modèle PK populationnel utilisé pour analyser nos résultats comporte une absorption biphasique durant laquelle une fraction de la dose administrée pénètre rapidement (temps d’absorption moyen : 27 min, IC % 19 – 38 min) dans le flux sanguin systémique pendant que l’autre partie, en provenance du site de dépôt, est redistribuée beaucoup plus lentement (demi-vie (T1/2) : 2.6 h, IC % 1.6 – 4.3 h) vers la circulation systémique. Une relation statistiquement significative entre l’âge de nos patients et la redistribution de l’AL suggère que la perméabilité tissulaire est augmentée avec l’âge. Manuscrit 4 : Une analyse PK-PD du comportement sensitif du bloc fémoral (CPT) a été effectuée. Le modèle développé a estimé à 20.2 ± 10.1 mg la quantité de ROP nécessaire au site d’action pour produire 90 % de l’effet maximal (AE90). À 2 X la AE90, le modèle prédit un début d’action de 23.4 ± 12.5 min et une durée de 22.9 ± 5.3 h. Il s’agit de la première étude ayant caractérisé le comportement sensitif d’un bloc nerveux périphérique. Manuscrit 5 : La troisième et dernière étude clinique a été conduite chez les patients qui devaient subir une chirurgie du genou sous rachianesthésie. Tout comme pour le bloc du nerf fémoral, le modèle PK le plus approprié pour nos données suggère que l’absorption systémique de la ROP à partir du liquide céphalo-rachidien est biphasique; c.à.d. une phase initiale (T1/2 : 49 min, IC %: 24 – 77 min) suivie (délai: 18 ± 2 min) d'une phase légèrement plus lente (T1/2 : 66 min, IC %: 36 – 97 min). L’effet maximal a été observé beaucoup plus rapidement, soit aux environs de 12.6 ± 4.9 min, avant de revenir aux valeurs de base 210 ± 55 min suivant l’administration de l’agent. Ces données ont permis d’estimer une AE50 de 7.3 ± 2.3 mg pour l'administration spinale. Conclusion : En somme, ces modèles peuvent être utilisés pour prédire l’évolution temporelle du bloc sensitif de l’anesthésie rachidienne et périphérique (fémorale), et par conséquent, optimiser l’utilisation clinique de la ROP en fonction des besoins des cliniciens, notamment en ce qui a trait à l’âge du patient. / Background & Objectives: To provide postoperative analgesia, the anesthesiologist has at his disposal a panel of different medications and also regional techniques of neural blockade. Loco-regional analgesia (central or peripheral) blocks conduction of painful influx to the central nervous system by the use of local anesthetics (LA). Among these drugs, ropivacaine (ROP), has an enormous potential given is long-acting efficacy and low incidence of toxicity. Currently, ROP is not licensed for use in spinal anesthesia (central block) in all countries due to a lack of data from controlled clinical trials. So far, research efforts on this topic have mainly focused on safety and dose-finding issues. In addition, the most appropriate dose for a peripheral nerve block has never been estimated empirically. Dosing recommendation for LAs should be site-specific and adapted to the intensity of the stimuli produced by a surgery and to the duration of analgesia required. Ultimately, these should guide clinicians in identifying the most appropriate block for the individual patients by taking into account demographic factors that may affect the pharmacokinetics (PK) and pharmacodynamics (PD) of LA overall objective of the current research) Analytical Method Validation Manuscript 1: First, a specific and sensitive assay has been developed and validated for the determination of ROP in human plasma. Biomarker Validation Manuscript 2: Second, the reliability of a neurostimulator measuring current perception threshold (CPT) was assessed in healthy volunteers. The device uses a constant transcutaneous electrical sine wave stimulus at different frequencies specific to pain-conducting fibers. Our results suggest that CPT are reliable and can be applied to characterize, in a quantitative manner, the sensory onset of a peripheral nerve block in a clinical setting. Clinical Studies Manuscript 3: The systemic absorption of ROP after a femoral nerve block in orthopedic patients was then characterized using extended rich PK-sampling, i.e. up to 4 days post-dosing. Our model used for data analysis confirms that, in a similar manner to neuraxial sites of LAs injection, the systemic absorption of ROP from the femoral space is biphasic, i.e. a rapid initial phase (mean absorption time of 25 min, % CI: 19 – 38 min) followed by a much slower phase (half-life (T1/2) of 3.9 h, % CI: 2.9 – 6.0 h). A significant age-related increase in the permeability of the LA was also observed in our elderly patients (n = 19, age = 62.6 ± 7.1 yr). Manuscript 4: A population PK-PD analysis of the sensory anesthesia (CPT) of ROP using our PK model was also performed. The effect-site amount producing 90% of the maximum possible effect (AE90) was estimated as 20.2 ± 10.1 mg. At 2 x AE90, the sigmoid Emax model predicted an onset time of 23.4 ± 12.5 min and a duration of 22.9 ± 5.3 h. To the best of our knowledge, this is the first PK-PD model developed for a peripheral nerve block. Manuscript 5: In the third and last study, a similar approach was used to characterise the PK-PD relationship of intrathecally administered ROP in patients undergoing minor lower limb surgery. The biphasic release of the agent from the intrathecal space was modeled using a rapid initial absorption phase (T1/2 of 49 min, % CI: 24 – 77 min) followed (lag-time of ~ 18 ± 2 min) by a slightly slower input rate (T1/2 of 66 min, % CI: 36 – 97 min). ROP maximal response was observed within 12.6 ± 4.9 min of dosing, with a subsequent return to baseline 210 ± 55 min after the administration of the LA. The effect-site amount producing 50 % of the Emax (AE50) was estimated at 7.3 ± 2.3 mg. Conclusion: Altogether, the proposed models can be used to predict the time-course of sensory blockade after a femoral nerve block and spinal anesthesia using ROP and to optimize dosing regimen according to clinical needs with regard to important cofactors such as age.

Introduction & Objectifs : Pour assurer l’analgésie postopératoire, l’anesthésiste dispose, en plus des différentes classes de médicaments administrés par voie orale ou intraveineuse, de diverses techniques pour bloquer l’influx nerveux douloureux en administrant les anesthésiques locaux (AL) de manière centrale ou périphérique. La ropivacaïne (ROP), un AL à longue durée d’action, est un médicament de première intention partout dans le monde, en raison de sa grande efficacité et de son faible risque de toxicité. Contrairement à certains pays, la ROP n'est toujours pas indiquée au Canada pour la rachianesthésie (bloc central) en raison d'un manque de données probantes. Jusqu'à présent, les efforts de recherche ont essentiellement porté sur la sécurité ainsi que sur la durée d’action du médicament lorsqu’administré par voie spinale. De plus, les doses optimales de ROP pour l’anesthésie régionale périphérique ne sont pas encore précisément connues. La posologie devrait être adaptée au site d’administration ainsi qu’à l’intensité et la durée du stimulus produit par la chirurgie. Ultimement, cela permettrait aux cliniciens d’identifier le régime optimal en fonction des facteurs démographiques qui pourraient affecter la pharmacocinétique (PK) et la pharmacodynamie (PD) de l’AL (objectif global de ces travaux). Validation de la Méthode Analytique Manuscrit 1 : Une méthode analytique spécifique et sensible permettant de déterminer les concentrations plasmatiques de ROP a d’abord été optimisée et validée. Validation du Biomarqueur Manuscrit 2 : Nous avons ensuite mis au point et évalué la fiabilité d’une méthode quantitative basée sur la mesure du seuil de perception sensorielle (CPT) chez le volontaire sain. Ce test nécessite l’application d’un courant électrique transcutané qui augmente graduellement et qui, selon la fréquence choisie, est capable de stimuler spécifiquement les fibres nerveuses impliquées dans le cheminement de l’influx nerveux douloureux. Les résultats obtenus chez les volontaires sains indiquent que la mesure CPT est fiable, reproductible et permet de suivre l’évolution temporelle du bloc sensitif. Études cliniques Manuscrit 3 : Nous avons ensuite caractérisé, pendant plus de 72 h, l’absorption systémique de la ROP lorsqu’administrée pour un bloc du nerf fémoral chez 19 patients subissant une chirurgie du genou. Le modèle PK populationnel utilisé pour analyser nos résultats comporte une absorption biphasique durant laquelle une fraction de la dose administrée pénètre rapidement (temps d’absorption moyen : 27 min, IC % 19 – 38 min) dans le flux sanguin systémique pendant que l’autre partie, en provenance du site de dépôt, est redistribuée beaucoup plus lentement (demi-vie (T1/2) : 2.6 h, IC % 1.6 – 4.3 h) vers la circulation systémique. Une relation statistiquement significative entre l’âge de nos patients et la redistribution de l’AL suggère que la perméabilité tissulaire est augmentée avec l’âge. Manuscrit 4 : Une analyse PK-PD du comportement sensitif du bloc fémoral (CPT) a été effectuée. Le modèle développé a estimé à 20.2 ± 10.1 mg la quantité de ROP nécessaire au site d’action pour produire 90 % de l’effet maximal (AE90). À 2 X la AE90, le modèle prédit un début d’action de 23.4 ± 12.5 min et une durée de 22.9 ± 5.3 h. Il s’agit de la première étude ayant caractérisé le comportement sensitif d’un bloc nerveux périphérique. Manuscrit 5 : La troisième et dernière étude clinique a été conduite chez les patients qui devaient subir une chirurgie du genou sous rachianesthésie. Tout comme pour le bloc du nerf fémoral, le modèle PK le plus approprié pour nos données suggère que l’absorption systémique de la ROP à partir du liquide céphalo-rachidien est biphasique; c.à.d. une phase initiale (T1/2 : 49 min, IC %: 24 – 77 min) suivie (délai: 18 ± 2 min) d'une phase légèrement plus lente (T1/2 : 66 min, IC %: 36 – 97 min). L’effet maximal a été observé beaucoup plus rapidement, soit aux environs de 12.6 ± 4.9 min, avant de revenir aux valeurs de base 210 ± 55 min suivant l’administration de l’agent. Ces données ont permis d’estimer une AE50 de 7.3 ± 2.3 mg pour l'administration spinale. Conclusion : En somme, ces modèles peuvent être utilisés pour prédire l’évolution temporelle du bloc sensitif de l’anesthésie rachidienne et périphérique (fémorale), et par conséquent, optimiser l’utilisation clinique de la ROP en fonction des besoins des cliniciens, notamment en ce qui a trait à l’âge du patient. / Background & Objectives: To provide postoperative analgesia, the anesthesiologist has at his disposal a panel of different medications and also regional techniques of neural blockade. Loco-regional analgesia (central or peripheral) blocks conduction of painful influx to the central nervous system by the use of local anesthetics (LA). Among these drugs, ropivacaine (ROP), has an enormous potential given is long-acting efficacy and low incidence of toxicity. Currently, ROP is not licensed for use in spinal anesthesia (central block) in all countries due to a lack of data from controlled clinical trials. So far, research efforts on this topic have mainly focused on safety and dose-finding issues. In addition, the most appropriate dose for a peripheral nerve block has never been estimated empirically. Dosing recommendation for LAs should be site-specific and adapted to the intensity of the stimuli produced by a surgery and to the duration of analgesia required. Ultimately, these should guide clinicians in identifying the most appropriate block for the individual patients by taking into account demographic factors that may affect the pharmacokinetics (PK) and pharmacodynamics (PD) of LA overall objective of the current research) Analytical Method Validation Manuscript 1: First, a specific and sensitive assay has been developed and validated for the determination of ROP in human plasma. Biomarker Validation Manuscript 2: Second, the reliability of a neurostimulator measuring current perception threshold (CPT) was assessed in healthy volunteers. The device uses a constant transcutaneous electrical sine wave stimulus at different frequencies specific to pain-conducting fibers. Our results suggest that CPT are reliable and can be applied to characterize, in a quantitative manner, the sensory onset of a peripheral nerve block in a clinical setting. Clinical Studies Manuscript 3: The systemic absorption of ROP after a femoral nerve block in orthopedic patients was then characterized using extended rich PK-sampling, i.e. up to 4 days post-dosing. Our model used for data analysis confirms that, in a similar manner to neuraxial sites of LAs injection, the systemic absorption of ROP from the femoral space is biphasic, i.e. a rapid initial phase (mean absorption time of 25 min, % CI: 19 – 38 min) followed by a much slower phase (half-life (T1/2) of 3.9 h, % CI: 2.9 – 6.0 h). A significant age-related increase in the permeability of the LA was also observed in our elderly patients (n = 19, age = 62.6 ± 7.1 yr). Manuscript 4: A population PK-PD analysis of the sensory anesthesia (CPT) of ROP using our PK model was also performed. The effect-site amount producing 90% of the maximum possible effect (AE90) was estimated as 20.2 ± 10.1 mg. At 2 x AE90, the sigmoid Emax model predicted an onset time of 23.4 ± 12.5 min and a duration of 22.9 ± 5.3 h. To the best of our knowledge, this is the first PK-PD model developed for a peripheral nerve block. Manuscript 5: In the third and last study, a similar approach was used to characterise the PK-PD relationship of intrathecally administered ROP in patients undergoing minor lower limb surgery. The biphasic release of the agent from the intrathecal space was modeled using a rapid initial absorption phase (T1/2 of 49 min, % CI: 24 – 77 min) followed (lag-time of ~ 18 ± 2 min) by a slightly slower input rate (T1/2 of 66 min, % CI: 36 – 97 min). ROP maximal response was observed within 12.6 ± 4.9 min of dosing, with a subsequent return to baseline 210 ± 55 min after the administration of the LA. The effect-site amount producing 50 % of the Emax (AE50) was estimated at 7.3 ± 2.3 mg. Conclusion: Altogether, the proposed models can be used to predict the time-course of sensory blockade after a femoral nerve block and spinal anesthesia using ROP and to optimize dosing regimen according to clinical needs with regard to important cofactors such as age.

Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-12-16T17:15:33Z No. of bitstreams: 1 marcellofonsecasalgadofilho.pdf: 9000247 bytes, checksum: a234119931ed8da56fb969e17bc8b078 (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-12-19T13:03:57Z (GMT) No. of bitstreams: 1 marcellofonsecasalgadofilho.pdf: 9000247 bytes, checksum: a234119931ed8da56fb969e17bc8b078 (MD5) / Made available in DSpace on 2016-12-19T13:03:57Z (GMT). No. of bitstreams: 1 marcellofonsecasalgadofilho.pdf: 9000247 bytes, checksum: a234119931ed8da56fb969e17bc8b078 (MD5) Previous issue date: 2010-04-14 / Introdução: O bloqueio do nervo dorsal do pênis (BNDP) e a anestesia local tópica (LT) com uma mistura eutética de prilocaína e lidacaína são técnicas de uso rotineiro, fácil aplicação e baixo índice de complicações na cirurgia de postectomia. Propôs-se avaliar qual delas apresenta melhor analgesia com menor efeito hemodinâmico na cirurgia de postectomia por Plastibell® em crianças. Pacientes e métodos: Este ensaio clínico randomizado foi conduzido com 41 meninos, submetidos à postectomia por Plastibell® divididos em dois grupos: LT e BNDP. O estudo foi aprovado pelo Comitê de Ética em Pesquisa em Humanos segundo as normas da declaração de Helsinki e pelo Clinical trials/FDA. Nos pacientes sorteados para a técnica LT, a pomada de mistura eutética de prilocaína e lidacaína era aplicada no prepúcio uma hora antes da cirurgia. Antes da indução anestésica, todas as crianças eram monitoradas com estetoscópio precordial e monitor multiparâmetro Datex Omeda®. A indução anestésica era padrão para os dois grupos, com concentração inspirada de sevoflurano a 8% sob máscara facial e ventilação espontânea. No grupo BNDP, fez-se o bloqueio do nervo dorsal do pênis com levobupivacaína a 0,5% na dose de 2mg/kg. Avaliaram-se a frequência cardíaca, a pressão arterial média, a frequência respiratória e os movimentos involuntários durante os momentos de indução anestésica, de bloqueio do nervo dorsal do pênis, um minuto após a incisão e no pós-operatório imediato. A dor foi avaliada na primeira e na vigésima quarta hora de pós-operatório, pela escala análogo visual de dor. Resultados: Os grupos foram homogêneos quanto à idade, peso, diâmetro da glande, comprimento do pênis e tempo cirúrgico. No grupo LT, observou-se uma tendência a aumento da freqüência cardíaca no momento 1 minuto pós-incisão (p = 0,073) e da pressão arterial media no momento 1 minuto pósincisão (p = 0,046). No grupo BNDP, houve aumento da freqüência cardíaca (p = 0,004) e da pressão arterial média (p = 0,016) no momento do bloqueio. Comparando os momentos de maiores estímulos hemodinâmicos em cada grupo (T2 no grupo LT e T1 no grupo BNDP), observamos um estímulo mais intenso no BNDP, com aumento significante da freqüência cardíaca (p = 0,001) e maior incidência de movimentos involuntários (p = 0,002). Não houve diferença na dor 7 na primeira e na vigésima quarta hora de pós-operatório entre os grupos estudados. A incidência de hematoma e edema em 24 horas de pós--operatório foi maior no grupo BNDP. Conclusão: A anestesia LT com a pomada de mistura eutética de prilocaína e lidacaína proporciona menor repercussão hemodinâmica e analgesia satisfatória ao procedimento de postectomia por Plastibell®, controle da dor pós-operatório e baixa incidência de complicações pós-operatórias em relação ao BNDP, quando ambas as técnicas estão associadas à anestesia geral inalatória com sevoflurano. / Introduction: The dorsal penile nerve block (DPNB) and local topical anesthesia (LT) with eutetic mixture lidocaine and prilocaine are current techniques with easy implementation and low complication rate in circumcision surgery. Herein, we evaluated which anesthetic technique provides better analgesia with less hemodynamic stimulation during circumcision with Plastibell® in children. Patients and methods: Forty-one boys who underwent circumcision with Plastibell® were divided at random into two groups: LT and DPNB. In LT group the ointment eutetic mixture lidocaine and prilocaine was applied to the foreskin one hour before surgery. Before inhalatory induction, all children were completely monitored. Inhalatory induction was standard for the two groups with 8% end-tidal concentration of sevoflurane on a facemask and spontaneous ventilation. After 10 minutes of anesthesia induction, the end-tidal sevoflurane concentration was decreased to 2%. In the DPNB a dorsal penile nerve block was done with levobupivacaine 0.5% (2 mg/kg). We evaluated the heart rate, respiratory rate mean arterial pressure, and involuntary movements in the moments of induction of anesthesia (T0); dorsal penile nerve block (T1); 1 minute post-incision (T2) and 1 minute after end of surgery (T3). And also pain 1 hour and 24 hours after surgery. Results: The groups were homogeneous when compared age, weight, diameter of the glands, penile length and surgical duration. In the LT group there was a tendency to increase Heart Rate at T2 (p = 0.073) and an increase of Mean Arterial Pressure at T2 (p = 0.046) when compared to the induction time. The DPNB group had an increase in Heart Rate (p = 0.004) and Mean Arterial Pressure (p = 0.016) at the block time (T1) when compared to T0 time. Comparing the moments of greatest hemodynamic stimulus for each group (T2 for LT and T1 for DPNB) we observed a more intense stimulus in DPNB group with a significant increase in Heart Rate (p = 0.001) and greater incidence of involuntary movements (57.1% vs. 10%; p = 0.002). There was no difference in the incidence of pain between the study groups. Post-operative complications were higher in DPNB, especially hematoma and edema. Conclusions: Anesthesia with eutetic mixture lidocaine and prilocaine provides satisfactory hemodynamic stable during circumcision with Plastibell®, pain control and less complication in the post 9 operative period when this technique is associated with general anesthesia with sevoflurane.

No description available.

No description available.

No / A significant number of people in the UK experience chronic pain, resulting in high levels of suffering and reduced quality of life. Management of chronic pain is complex, time consuming and not always successful. Good communication between patients and healthcare professionals is essential to ensure realistic treatment plans and outcomes can be negotiated. Accurate assessment is also key, and nurses play a fundamental role in ensuring patients with chronic pain receive the most appropriate care.

Au cours des vingt dernières années, l’anesthésie régionale est devenue, autant en médecine vétérinaire qu’humaine, un outil essentiel à l’élaboration de protocoles analgésiques péri-opératoires. Parmi l’éventail de techniques mises au point en anesthésie canine, le bloc paravertébral du plexus vertébral (PBPB) et sa version modifiée sont d’un grand intérêt pour toute procédure du membre thoracique, dans sa portion proximale. Toutefois, l’essentiel des données publiées à ce jour provient d’études colorimétriques, sans évaluation clinique, et peu d’information est disponible sur les techniques de localisation nerveuse envisageables à ce site. Notre étude visait à décrire une approche échoguidée du PBPB modifié, puis à caractériser ses paramètres pharmacocinétiques et pharmacodynamiques après administration de lidocaïne (LI) ou lidocaïne adrénalinée (LA). Huit chiens ont été inclus dans un protocole prospectif, randomisé, en aveugle et croisé, réparti sur trois périodes. L’impact pharmacodynamique du bloc effectué avec LI ou LA a été évalué régulièrement pour 180 min suivant son exécution. Le traitement à l’adrénaline n’a pas démontré d’impact significatif (P = 0,845) sur la durée du bloc sensitif, tel qu’évalué par un stimulus douloureux mécanique appliqué aux dermatomes ciblés. À l’opposé, l’atteinte proprioceptive évaluée par la démarche a été trouvée prolongée (P = 0,027) et le bloc moteur mesuré par le pic de force verticale (PVF) au trot sur la plaque de force s’est avéré plus marqué (PVF réduit; P = 0,007) sous LA. À l’arrêt comme au trot, le nadir de la courbe PVF-temps a été trouvé retardé (P < 0,005) et la pente ascendante de retour aux valeurs normales adoucie (P = 0,005). Parallèlement aux évaluations cliniques, des échantillons plasmatiques ont été collectés régulièrement afin de quantifier et décrire le devenir pharmacocinétique de la lidocaïne. Parmi les trois élaborés, un modèle bi-compartimental doté d’une double absorption asynchrone d’ordre zéro a finalement été sélectionné et appliqué aux données expérimentales. Sous LA, la Cmax a été trouvée significativement diminuée (P < 0,001), les phases d’absorption prolongées [P < 0,020 (Dur1) et P < 0,001 (Dur2)] et leurs constantes réduites [P = 0,046(k01) et P < 0,001 (k02)], le tout en concordance avec les effets proprioceptifs et moteurs rapportés. Bien que l’extrapolation du dosage soit maintenant théoriquement envisageable à partir du modèle mis en lumière ici, des études supplémentaires sont encore nécessaires afin d’établir un protocole de PBPB d’intérêt clinique. L’analyse sur plaque de force pourrait alors devenir un outil de choix pour évaluer l’efficacité du bloc dans un cadre expérimental. / Over the last decade, regional anaesthesia has become a gold standard for peri-surgical management in veterinary medicine. Among the many techniques developed for analgesia in dogs, the paravertebral brachial plexus block (PBPB) is of great interest when targeting the proximal half of the thoracic limb. Yet, most available data on this technique is based on colorimetric protocols rather than clinical evaluation, and there are very few published results for PBPB execution using nerve location techniques. Through this work, we wished to describe an ultrasound-guided approach of the PBPB and characterize its pharmacokinetic/ pharmacodynamic parameters when executed with either lidocaine alone (LI) or combined to adrenaline (LA). Eight dogs were included in a prospective, randomised, blinded, crossover protocol performed over three distinct periods. Pharmacodynamic impact of LI and LA was compared for 180 minutes after block administration. No significant difference (P = 0.845) was noted between treatments regarding length of the sensitive block, as evaluated regularly through a mechanical painful stimulus applied to selected dermatomes. On the opposite, gait examination showed a longer proprioceptive deficit using LA (P = 0.027). Motor block measured with dynamic force plate analysis showed a lower peak vertical force with LA than LI (P = 0.007). For both dynamic and static evaluations, nadir was clearly delayed (P < 0.005) and the ascending slope back to baseline significantly softened (P = 0.005) in the LA group. Throughout block execution and evaluation, blood samples were collected regularly in order to quantify and describe lidocaine kinetics. Models where developed and compared. A two-compartment model with dual zero-order absorption processes was selected as the best fit for our experimental data. Cmax proved to be significantly reduced with LA (P < 0.001), thus reducing potential toxicity. Absorption phase was prolonged [P < 0.020 (Dur1) and P < 0.001 (Dur2)] and zero-order absorption constant rates lowered [P = 0.046(k01) and P < 0.001 (k02)] following adrenaline addition, in accordance with the previously noted prolonged gait and motor effects. Though dosage extrapolation is now possible using the model developed and tested here, further studies would be needed to establish a PBPB protocol of more clinical interest. Then, force plate analysis could become a key tool for block quality assessment, as both dynamic and static measurements proved to be the reliable ways to collect ground reaction force (GRF) data.